On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials

Gynecologic Cancer

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial

★ 3 Recommended and commented by Dr Andreas Müller, Faculty Member

★ 1 Recommended by Prof. Dr Beat Thürlimann, Faculty Member

Lancet Oncol

Post CCB, de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Leary A, Ottevanger PB, McCormack M, Khaw P, D'Amico R, Fyles A, Chargari C, Kitchener HC, Do V, Lissoni A, Provencher D, Genestie C, Nijman HW, Whitmarsh K, Jürgenliemk-Schulz IM, Feeney A, Lutgens LCHW, Bouma J, Leon-Castillo A, Nout RA, Putter H, Bosse T, Creutzberg CL

doi: 10.1016/S1470-2045(25)00379-1

Genitourinary Cancer

Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Eur Urol

Nguyen DD, Tadayon Najafabadi B, Lin L, Kwong JCC, Miller E, Zlotta AR, Fleshner NE, Hird AE, Lofters AK, Wallis CJD, Rosella LC, Dahm P, Guyatt G, Kulkarni GS

doi: 10.1016/j.eururo.2026.04.005

Gastrointestinal Cancer

Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial

JAMA Oncol

Zhang GQ, Meyerhardt JA, Shi Q, Twombly T, Pederson L, Ma C, Väyrynen JP, Zhao M, Takashima Y, Shergill A, Kumar P, Couture F, Kuebler P, Krishnamurthi S, Tan B, O'Reilly EM, Giannakis M, Ogino S, Jurdi A, Sharma S, Aleshin A, Shields AF, Nowak JA

doi: 10.1001/jamaoncol.2025.5144

RECOMMENDED

Breast Cancer

Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial

★ 1 Recommended by Prof. Dr Beat Thürlimann, Faculty Member

Lancet Oncol

Yuan J, Bi XW, Hua X, Huang H, Cai L, Zhao L, Chen QJ, Chen XX, Wang XL, Lin Y, Zhang AQ, Zhong YY, Xu F, Huang JJ, An X, Shi YX, Wang X, Wang SS, Xue C, Yuan ZY

doi: 10.1016/S1470-2045(25)00545-5

Genitourinary Cancer

Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer

Ann Oncol

Parker CTA, Huang HC, Grist E, Mendes L, Yamashita R, Croucher D, Sachdeva A, Murphy L, Liu VYT, Vidal SS, Todorovic T, Lall S, Goncalves M, Thakali S, Wingate A, Zakka L, Wetterskog D, Nowakowska K, Amos CL, STAMPEDE Collaborators, Berney DM, Tran PT, Spratt DE, Sydes MR, Brown LC, Zhao SG, Nguyen P, Clarke NW, Sweeney CJ, Stewart EL, Parmar MKB, Esteva A, James ND, Attard G

doi: 10.1016/j.annonc.2026.05.708

Genitourinary Cancer

Survival trend in metastatic prostate cancer two decades of real-world data on overall survival from Germany

Prostate Cancer Prostatic Dis

Sondermann M, Stehr A, Hirtsiefer C, Menzel V, Buttmann-Schweiger N, Flemming PW, Kraywinkel K, Thomas C, Boehm K

doi: 10.1038/s41391-026-01092-w

Genitourinary Cancer

Confirmation of Prostate-specific Antigen (PSA) Values Improves Prostate Cancer Screening in Early Middle-Aged Men - Data from the PROBASE Trial

Eur Urol

Krilaviciute A, Becker N, Carlsson SV, Kaaks R, Seibold P, Lakes J, Al-Monajjed R, Kuczyk M, Harke NN, Kanaan MR, Debus J, Grott CA, Liermann J, Gschwend JE, Herkommer K, Göldner VA, Kristiansen G, Antoch G, Schimmöller L, Arsov C, Hadaschik B, Albers P

doi: 10.1016/j.eururo.2026.06.016

Genitourinary Cancer

Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE Registry

Eur Urol

Karpinski MJ, Hoberück S, Fendler WP, Civan C, Bundschuh RA, Thomas C, Bjartell A, Trägårdh E, Soeterik TFW, Evangelista L, Vondrak A, Rasul S, Forner L, Giorgio AD, Scholtissek H, Miksch J, Holzgreve A, Lanfranchi F, Rahbar K, Hofman MS, Rauscher I, Güven O, Eiber M, Ayati N, Umutlu L, Herrmann K, Hadaschik B, Emmett L

doi: 10.1016/j.eururo.2025.10.013

Genitourinary Cancer

Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Long-term Data from the SAKK 09/10 Randomised Phase 3 Trial

Eur Urol

Ghadjar P, Hayoz S, Zwahlen DR, Hölscher T, Arnold W, Polat B, Hildebrandt G, Hoffmann E, Plasswilm L, Papachristofilou A, Schär C, Sumila M, Zaugg K, Guckenberger M, Ost P, Reuter C, Bosetti DG, Khanfir K, Riesterer O, Beck M, Thalmann GN, Aebersold DM, Swiss Group for Clinical Cancer Research (SAKK)

doi: 10.1016/j.eururo.2025.12.020

Related content

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial

Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial

Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial

Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer

Survival trend in metastatic prostate cancer two decades of real-world data on overall survival from Germany

Confirmation of Prostate-specific Antigen (PSA) Values Improves Prostate Cancer Screening in Early Middle-Aged Men - Data from the PROBASE Trial

Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE Registry

Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Long-term Data from the SAKK 09/10 Randomised Phase 3 Trial